The controversial approval of Biogen's drug Aduhelm (aducanumab) in the US hasn't been followed by a corresponding approval in the EU, the company itself reports in a press release on Wednesday.
An oral presentation held by Biogen in November was followed by a so-called trend vote from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). It resulted in members of the committee adopting a negative opinion on the drug and thus no backing for a potential marketing approval in the EU. A formal rejection is expected to be announced at the CHMP's monthly meeting in December.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Orphazyme's creditors to vote on sales agreement at end of May
Sunday’s sales agreement between US-based Kempharm and Orphazyme will be decided on May 30, when the company’s creditors meet to vote on the proposal.
Novo Holdings establishes new firm managed by biotech veterans
Co-Founder and former CSO of Orphazyme Thomas Kirkegaard Jensen and Bo Rode Hansen, CEO of Scandion Oncology, are both involved in another secret venture backed by Novo Holdings.
Diabetes center CEO: New Eli Lilly drug is worthy opponent for Novo Nordisk's Ozempic
Allan Flyvbjerg, CEO of Steno Diabetes Center in Copenhagen, says Eli Lilly’s tirzepatide has proved itself a fierce challenger to Novo Nordisk’s newest generation of diabetes drugs.
In a world of options, Genmab's CEO chose partnerships
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.
Analyst predicts slow start for Leo Pharma's Adtralza in UK
The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.
Analytical Coordinator for Analytical Development 
Director for innovative pre-clinical testing unit 
Clinical Trial Administrator 
Nordic Medical Affairs Manager 
Consultant Manager 
Clinical Project Manager 
System Sales Development Consultant - Investment Projects, Merck Millipore 
IT Solution Architect for R&D and Global Quality applications 
IRT Manager, Clinical Drug Supply 
Director Global Engineering 
Client Talent Acquisition Specialist 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Procurement Process Excellence Specialist